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Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. 
Lack of targeted therapies and chemotherapy resistance remain key issues, the latter being linked to 
cancer stem cells (CSCs). Previously, we showed that bacopaside II induces vacuoles and cell death 
in breast cancer cells, but the mechanism remains unknown. We aim to study cell death types 
(apoptosis, methuosis or necroptosis), and determine if bacopaside II can overcome resistance.  
Methods: TNBC cell line, MDA-MB-231, was treated with bacopaside II. Caspase-3/7 activation 
and labelled-dextran uptake were measured to indicate apoptosis and methuosis respectively. 
Propidium iodide (PI) influx, with and without necrostatin-1, and immunoblot of necroptosis proteins 
(MLKL,  phosphorylated MLKL) were measured to indicate necroptosis. Scaffold-less 3D-cultured 
model was established and compared to 2D-cultured cells, to measure expression of CSC markers 
(OCT4, NANOG), and changes in IC50 to paclitaxel, doxorubicin, 5-fluorouracil or bacopaside II to 
indicate resistance/sensitivity. 
Results: With bacopaside II treatment, caspase-3/7 was not activated and dextran did not localize 
within vacuoles. Bacopaside II induced a dose-dependent increase in PI-positivity and increased 
pMLKL:MLKL ratio. Necrostatin-1 (50 µM) significantly reduced (p < 0.05) PI-positivity by 20% 
and 21% with 20 and 30 µM bacopaside II respectively, compared to vehicle control. 3D-cultured 
MDA-MB-231 displayed increases (p < 0.0001) in OCT4 (3.4-fold) and NANOG (38-fold) 
expression, and increases (p < 0.0001) in IC50 for paclitaxel (2.1-fold), doxorubicin (2.2-fold) and 
5-fluorouracil (1.4-fold) but not bacopaside II, relative to 2D-cultured cells.  




1. Introduction  
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, with 
approximately 400,000 new cases worldwide each year1. It is characterised by the absence of human 
epidermal receptor-2, progesterone and estrogen receptors, resulting in the lack of targeted treatment2. 
Women with TNBC have a poorer prognosis and higher rate of metastasis due to residual cancer 
burden compared to other breast cancer subtypes, despite having an initial good response to 
neoadjuvant chemotherapies3. Furthermore, chemotherapy-induced toxicity also takes a toll on the 
patients, affecting quality of life and treatment outcomes4. 
Due to heterogeneity, TNBC can be further categorized into subgroups based on gene-expression 
profile. Recently, three molecular clusters (C1-3) were defined, whereby C1 expresses luminal 
androgen receptor, while C2 and C3 are basal-like5. Additionally, C2 is immunosuppressive, while 
C3 expresses adaptive immune phenotype associated with immune checkpoint upregulation including 
PD1 and PD-L15. This suggests that responses to current therapies will be different in each cluster. 
Furthermore, only C3 subset would respond to immunotherapy. 
Cancer heterogeneity can be explained by two hypotheses: clonal evolution model and cancer stem 
cell (CSC) model6. The former postulates that all cancer cells have tumorigenic potential and 
sequential mutations generates heterogeneity within a tumour, while the latter proposed that only a 
subset of cancer cells known as CSC have tumour-propagating potential6. Extensive intratumor 
heterogeneity often leads to the development of resistance7. In basal-like breast cancer, CSC 
phenotype CD44+CD24-/low and ALDH1 positivity were associated with higher chemoresistance, 
recurrence, metastasis, and poorer progression-free survival (PFS) and overall survival (OS)8. 
Moreover, TNBC patients with high OCT4 and NANOG expression have poorer PFS and OS9, 10. In 
all, the lack of targeted therapies, heterogeneity, and development of resistance in TNBC constitute 
the need for an alternative therapy. 
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Our group have been investigating bacopaside II, a purified compound from medicinal herb Bacopa 
monnieri. An extract of this herb, Brahmi, is available over the counter and has been used for centuries 
for memory enhancement and more recently as a sedative, with limited adverse effects reported11-13. 
Bacopaside II belongs to the family of triterpenoid saponins. Other family members exhibit anti-
inflammatory effects, and anti-cancer properties including promoting apoptosis and autophagy, while 
inhibiting proliferation, metastasis and multidrug resistance14. A well-studied example, bacoside A/B, 
displayed anti-cancer effects in breast, colon, lung and brain cancer15-18. Furthermore, bacopaside II 
treatment have been reported to impair migration in colorectal cancer cells by blocking aquaporin-1 
channels19. 
Previously, our group reported that bacopaside II induced vacuole formation in endothelial cells, 
breast and colorectal cancer cells by unknown mechanisms20-22. These findings were similar to a study 
from John et al.17, whereby bacoside A (containing bacopaside II) also led to vacuole formation in 
glioblastoma cells, detected by tetramethylrhodamine-dextran (TMR-dextran) uptake and 
immunostaining of endosomal trafficking and lysosomal membrane proteins (Rab7, LAMP1), 
suggesting methuosis17. Methuosis is characterized by excessive macropinocytosis and disruption of 
macropinosome trafficking, leading to accumulation of large cytoplasmic vacuoles which ruptures 
the cell membrane23-25. Hence, methuosis will be investigated as a possible mechanism of cell death 
induced by bacopaside II. 
Furthermore, we also reported significant increase in annexin-V-positive/propidium iodide (PI)-
negative and annexin-V-positive/PI-positive populations in breast cancer and colorectal cancer cells, 
when treated with bacopaside II alone or in combination with bacopaside I20, 21. It was suggested that 
apoptosis was the mechanism of cell death20, 21. However, annexin-V and PI positivity are not 
conclusive hallmarks of apoptosis26. Necroptosis, a programmed necrosis pathway, can also result in 




Figure 1: Interplay between necroptosis and apoptosis. 
Necroptosis can be activated by ligand binding to tumour necrosis factor (TNF) family death domain 
receptors, which leads to activation of receptor-interacting serine-threonine protein kinase 1 and 3 
(RIPK1/3), and executor mixed-lineage kinase domain-like (MLKL) protein by phosphorylation (p) 
(Figure 1)29-31. Subsequently, pMLKL oligomerizes and translocates to cell membrane to form pores, 
which results in ion (Ca2+, Na+, Mg2+) influx, cell rupture and the release of damage-associated 
molecular patterns (DAMPs)29-33. With a compromised cell membrane, PI and annexin-V will be able 
to bind to nucleic acids and membrane phosphatidylserine respectively. Hence, markers of apoptosis 
(caspase-3/-7)34 and necroptosis (MLKL, pMLKL) will be further investigated following bacopaside 
II treatment. 
Bacopaside II also reduced cell growth, migration and survival in endothelial cells, breast and 
colorectal cancer cells19-22. Since the maintenance of normal cell growth, migration and survival is 
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regulated by PI3K-Akt-mTOR signalling pathway, bacopaside II may affect this pathway35. 
Furthermore, apoptosis, methuosis and necroptosis were found to be regulated by PI3K-Akt-mTOR 
signalling pathway, making this a relevant pathway to investigate the effects of bacopaside II36-38. 
The goal for this project is to elucidate the mechanism of cell death of bacopaside II by investigating 
the markers of apoptosis, methuosis and necroptosis, and transcriptomic changes in PI3K-Akt-mTOR 
signalling pathway. Apoptosis is a common mechanism of cell death caused by chemotherapies39. 
However, signalling pathways regulating apoptosis are often dysregulated, leading to the 
development, progression and resistance of the cancer39. Non-apoptotic cell death pathways, such as 
necroptosis or methuosis, may be able to bypass apoptosis resistance and benefit cancer patients. 
Particularly for necroptosis, the release of DAMPs initiates immunogenic responses whereby tumours 
can be rendered sensitive or be re-sensitised to immunotherapy regimens29.  
Here, we hypothesize that bacopaside II causes cell death through a non-apoptotic pathway, 
necroptosis or methuosis, which can overcome the resistance induced in a 3D-cultured cell model. 
The effects of bacopaside II are also postulated to influence PI3K-AKT-mTOR signalling pathway.  
1.1 AIMS: 
i) Elucidate the type of cell death caused by bacopaside II through analysis of molecular 
markers of apoptosis, methuosis and necroptosis. 
ii) Determine the change in transcript expression within PI3K-AKT-mTOR signalling pathway 
with bacopaside II, using quantitative PCR (qPCR) on TaqMan® human PI3K signalling 
arrays. 
iii) Develop resistance in MDA-MB-231 by culturing in 3D-culture and test the efficacy of 
chemotherapies (paclitaxel, doxorubicin, 5-fluorouracil) and bacopaside II on these chemo-
resistant cells.  
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2. Materials and Methods 
2.1 Drug preparation 
The analytical standard bacopaside II (≥ 95% purity by HPLC) was obtained from Sigma-Aldrich (St 
Louis, MO, USA), and dissolved in methanol. Paclitaxel and 5-fluorouracil were purchased from 
Sigma-Aldrich, dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich). Doxorubicin 
hydrochloride (Pfizer Australia Pty Ltd, Sydney, NSW, Australia) was obtained from The Queen 
Elizabeth Hospital, Adelaide.  
2.2 Cell line and cell culture  
TNBC cell line, MDA-MB-231, was obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA) and maintained in Leibovitz's L-15 Medium (Life Technologies, Eugene, OR, 
USA), supplemented with 10% heat-inactivated foetal bovine serum (Corning, NY, USA), 200 U/mL 
of penicillin and 200 µg/mL of streptomycin (Life Technologies), at 37 °C and 0% CO2 in air. Cells 
were mycoplasma-free (MycoAlertTM Mycoplasma detection kit; Lonza, Mt Waverley, VIC, 
Australia).  
2.3  Apoptosis assay 
To determine if cell death occurred through apoptosis, caspase-3/-7 (CellEvent™ caspase-3/7; 
ThermoFisher Scientific, Waltham, MA, USA) activation was measured using fluorescence channel 
of IncucyteS3 live-cell imaging system (Essen Bioscience, Ann Arbor, MI, USA) at 24 h. Cells were 
seeded at 3.3 × 103 cells per well in a 96-well flat bottom plate (Corning) and treated with various 
doses of bacopaside II (Table 1), with 0.25 µM staurosporine (Sigma-Aldrich) as positive control. 
Results were analysed by Prism v8.4.3 (GraphPad software, CA, USA), using one-way analysis of 
variance (ANOVA) with Dunnett’s multiple comparison and presented as average caspase-3/-7 
counts per image with mean ± standard error mean (SEM) (n = 6 per dose). 
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Table 1: Treatment doses 
 
2.4 Dextran-uptake assay 
To investigate if bacopaside II induced macropinocytosis, 75-kDa TMR-dextran (Sigma-Aldrich) 
uptake was measured to indicate macropinosomes40. Cells were seeded at 1 × 105 cells per well in a 
8-well chamber slides (ThermoFisher Scientific), treated with 15 µM bacopaside II for 6 h, and 1 h 
of incubation with 1 mg/ml TMR-dextran40. Cells were washed with Dulbecco’s phosphate buffered 
saline (DPBS; ThermoFisher Scientific), fixed with 4% paraformaldehyde (Sigma-Aldrich), and 
stained with 4′,6-diamidino-2-phenylindole (DAPI; ThermoFisher Scientific) nuclear stain. 
Representative images from three experiments were captured using Zeiss Axio observer Z1 inverted 
microscope (Carl Zeiss, Jena, Germany). 
2.5  Effects of bacopaside II on cell membrane integrity  
Cells were seeded at 3.3 × 103 cells per well in a 96-well plate and treated with bacopaside II as per 
Table 1 (n = 6, per dose). Propidium iodide (Sigma-Aldrich) was used at 2.5 µg/mL to indicate 
disrupted membrane integrity. Live-cell imaging was performed at 2 h intervals for two days using 
IncucyteS3, with phase contrast and red fluorescence images being captured. Data were analysed 
Drug Doses Vehicle 
Paclitaxel (nM) 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25, 50, 100 0.01% DMSO 
Doxorubicin (µM) 0.098, 0.20, 0.39, 0.78, 1.56, 3.13, 6.25, 25, 100 Media 
5-flurouracil (µM) 0.78, 1.56, 3.13, 6.25, 12.5, 25, 50, 100, 200 0.13% DMSO 
Bacopaside II (µM) 2.5, 5, 10, 15, 20, 30 2% methanol 
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using Prism v8.4.3 and presented as average PI counts per image with 95% confidence interval (CI) 
across two days. Two-way ANOVA with Dunnett’s multiple comparison was performed to determine 
significant changes at each timepoints compared to vehicle control.  
Further investigation included necroptosis inhibitor, necrostatin-1, to inhibit PI-influx. Cells were 
treated with 20 or 30 µM bacopaside II, along with 10, 20, 30, 40 and 50 µM necrostatin-1 for each 
bacopaside II treatment. Vehicle control contained only bacopaside II, and each condition contained 
2.5 µg/mL PI. Results were analysed relative to vehicle control, using one-way ANOVA test with 
Dunnett’s multiple comparison and presented as average PI counts per image with mean ± SEM (n = 
6) at 12 h. 
2.6 Western immunoblot for MLKL and pMLKL after bacopaside II treatment 
MDA-MB-231 (5 x 105) were seeded into wells of a 6-well plate (Corning) and incubated overnight. 
Next, the cells were treated with bacopaside II for 4 h, lysed using RIPA Lysis and Extraction Buffer 
supplemented with Halt Protease Inhibitor Cocktail and Halt Phosphatase Inhibitor Cocktail (Thermo 
Fisher Scientific), homogenised by passing through a 26-gauge needle, and centrifuged at 17,000 x g 
for 15 min at 4 °C to remove insoluble cell debris. Total protein was quantified using Bio-Rad Protein 
Assay (Bio-Rad, Hercules, CA, USA) and 50 g was resolved by denaturing electrophoresis using 4-
15% Mini-PROTEAN TGX Stain-Free precast gels and transferred to 0.2 m polyvinylidene 
difluoride membranes using a Trans-Blot Turbo Transfer System (Bio-Rad). Membranes were 
blocked with either 5% skim milk (for MLKL) or 5% BSA (for pS358-MLKL) in Tris-buffered saline 
supplemented with 0.05% (v/v) Tween-20 (TBST) for at least 1 h. Membranes were incubated at 4oC 
overnight with 1:1000 dilution anti-MLKL (clone [EPR17514], ab184718) in 0.1% milk in TBST, or 
1:1000 anti-pS358-MLKL ([EPR9514], ab187091) in 2% BSA in TBST. Finally, membranes were 
washed 5 times with TBST, incubated with 1:2000 goat anti-rabbit (H+L)-HRP conjugated secondary 
antibody (Bio-Rad) for 1 h and visualised using Clarity Western ECL Blotting Substrate with a 
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ChemiDoc Gel Imaging System (Bio-Rad). The MLKL and pMLKL bands were quantified and 
normalised to total protein using Image Lab Software v6.0.1 (Bio-Rad). 
2.7 3D-culture to establish resistant cell model 
To establish a resistant model, three biological replicates of MDA-MB-231 were cultured in 3D 
scaffold-less conditions for four weeks to enhance for stem cell-like phenotypes41. Briefly, cells were 
seeded at 4 × 104 cells per well in ultra-low attachment (ULA) 6-well plates (Corning) using 
MammocultTM media (STEMCELLTM Technologies, Vancouver, Canada), supplemented with 10% 
MammoCultTM proliferation supplement, 4 μg/mL heparin solution, 0.48 μg/mL hydrocortisone stock 
solution, 200 U/mL of penicillin and 200 µg/mL of streptomycin (Life Technologies). 
Mammospheres were passaged weekly by dissociating with 2% ethylenediaminetetraacetic acid 
(Sigma-Aldrich) in PBS and reseeding at 4 × 104 cells per well41. Mammospheres were dissociated 
and reseeded for subsequent experiments (Figure 2). Herein, these cells are termed 3D-cultured cells.  
   
Figure 2: Experiments using 3D-cultured cells. 
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2.8 RNA extraction and cDNA synthesis  
RNA was isolated for TaqMan® array human PI3K signalling 96-well plates and TaqMan® gene 
expression assays (see below) using PureLink RNA Mini Kit (Life Technologies) according to 
manufacturer’s instructions. RNA was quantified using NanoDropTM 2000 spectrophotometer 
(ThermoFisher Scientific). Total RNA (1.5 μg for TaqMan® array human PI3K signalling and 150 
ng for TaqMan® gene expression assays) was reverse transcribed using SuperScriptTM IV VILO 
Master Mix (ThermoFisher Scientific) following manufacturer’s instruction. 
2.9 PI3K-Akt-mTOR gene expression array  
Transcript expression within human PI3K signalling pathway were studied using TaqMan® array 
human PI3K signalling 96-well plate (Applied BiosciencesTM, Foster City, CA, USA), containing 92 
genes involved in PI3K signalling pathway. 3D-cultured cells were seeded at 5 × 103 cells per well 
in 96-well ULA plates (Corning) and treated with 15 µM bacopaside II or vehicle control (2% 
methanol) for 24 h. Master mix was prepared according to manufacturer’s protocol and 10 µL was 
added to each well of the 96-well plate. Three biological replicates were used for each condition. 
Reactions were performed using ViiATM 7 Real-Time PCR System (Life Technologies) with 
activation for 2 min at 95 °C, followed by 40 cycles of 1s at 95 °C and 20s at 60 °C. Results were 
calculated using the 2-ΔΔCt relative quantification (RQ) method, relative to vehicle control, and 
normalized to HPRT1, GUSB and GAPDH reference genes. Multiple t-test with Holm-Sidak 
correction was performed and adjusted for false discovery rate (FDR), with 5% cut-off.  
2.10 qPCR for stem cell-like markers, NANOG and OCT4 
To determine phenotypic changes between 3D-cultured (1-week, 3-weeks, 4-week) to 2D-cultured 
cells, transcript expression of Nanog homeobox pseudogene-1 (NANOG; Hs04399610_g1; Applied 
Biosystems) and octamer-binding transcription factor-4 (OCT4; Hs00742896_s1; Applied 
Biosystems) were determined by qPCR. Human hypoxanthine phosphoribosyltransferase-1 (HPRT1; 
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Hs99999909_m1; Applied Biosystems) was used as reference gene and 10 µL reactions (1 µL cDNA, 
0.5 µL HPRT1, 0.5 µL OCT4/NANOG, 7 µL TaqManTM Fast Advanced Master Mix) were performed 
using conditions in section 2.9. Three biological replicates, with three technical replicates were used. 
Results were calculated using 2-ΔΔCt RQ method, relative to 2D-cultured cells and normalized to 
HPRT1 reference gene.  
Similar procedure was performed on 4-week 3D-cultured cells that were reseeded as monolayer 
required for the drug sensitivity assays (five days), to confirm that NANOG and OCT4 expression 
was maintained and the cells were phenotypically different to 2D-cultured cells. 
2.11 Drug sensitivity assay 
The half-maximal inhibitory concentration (IC50) in response to chemotherapies (paclitaxel, 
doxorubicin, 5-fluorouracil) or bacopaside II were measured and compared between 2D-cultured and 
4-weeks 3D-cultured cells. Cells were seeded as monolayer at 3.3 × 103 cells per well in a 96-well 
flat bottom plates and treated with chemotherapies or bacopaside II shown in Table 1. IC50 was 
determined using IncucyteS3 confluence measurement at day five. To validate IncucyteS3 results, 
crystal violet assay (CVA) was performed as described previously21. Cells were seeded and treated 
similarly for five days, before being stained with crystal violet (Sigma-Aldrich). Absorbance was 
measured at 595 nm using FLUOstar Optima microplate reader (BMG Labtech, Ortenberg, Germany) 
at day five. Results were analysed using extra sum-of-squares F-test (Prism v8.4.3) to compare IC50 




3.1 Caspase-3/-7 was not activated by bacopaside II 
To investigate the type of cell death that had occurred, caspase-3/-7 activation was investigated as a 
hallmark for apoptosis. Relative to vehicle control, results showed no significant differences in 
caspase-3/-7 counts with each bacopaside II treatment (Figure 3).  
   
Figure 3: Caspase-3/-7 activation in MDA-MB-231 treated with bacopaside II. 
Results were analysed using one-way ANOVA with Dunnett’s multiple comparison and 
expressed as mean ± SEM (n = 6). p > 0.05 (ns). 
3.2 TMR-dextran did not colocalize within vacuoles with bacopaside II treatment 
To test whether bacopaside II causes macropinocytosis, TMR-dextran uptake was measured. Vacuole 
formation was prominent at 6 h of treatment, but 75-kDa TMR-dextran did not colocalize within these 
vacuoles (Figure 4). 
































Figure 4: TMR-dextran uptake with bacopaside II. Red arrows: vacuoles; Orange: 
TMR-dextran; Blue: Nuclei. Representative images (n = 3) were captured at 10X 
magnification (inset magnified view). 
3.3 Membrane integrity was disrupted by bacopaside II  
The kinetics of cell membrane permeability with bacopaside II treatment was investigated using PI. 
PI count increased for each treatment across two days. Comparing to vehicle control, rapid PI-influx 
was observed with 20 and 30 µM of bacopaside II, whereby significant differences (p < 0.05) in PI-
influx was observed from time points 4 h and 2 h respectively (Figure 5).  
 
Figure 5: Kinetics of membrane permeability with bacopaside II. Two-way ANOVA 
with Dunnett’s multiple comparison test was used to compare difference in PI-influx 
relative to vehicle control (n = 6).   
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3.4 Bacopaside II may induce necroptosis 
Since rapid PI-influx was observed with 20 and 30 µM of bacopaside II treatment, the possibility of 
necroptosis was explored using necrostatin-1, an inhibitor of RIPK1. With 20 µM bacopaside II, 40 
and 50 µM necrostatin-1 decreased 20.3% (p < 0.05) and 19.8% (p < 0.05) of PI count respectively, 
as compared to vehicle control (Figure 6A). With 30 µM bacopaside II, only 50 µM of necrostatin-1 
decreased PI-influx (20.8%, p < 0.05) (Figure 6B). 
To further validate necroptosis pathway, ratio of the normalized intensity of pMLKL to MLKL 
(pMLKL:MLKL) protein expression was measured (Figure 6C-6E). With 15, 20 and 30 µM 
bacopaside II treatment, pMLKL:MLKL increased by 2-fold, 3-fold and 7-fold respectively, relative 





Figure 6: Investigating necroptosis pathway with bacopaside II. PI-influx with 
various doses of necrostatin-1 and (A) 20 µM or (B) 30 µM bacopaside II treatment at 
12h. Results were analysed relative to vehicle control, using one-way ANOVA with 
Dunnett’s multiple comparison and expressed as mean ± SEM (n = 6). * < 0.05, ns > 0.05. 
Western blot on (C) MLKL, (D) pMLKL and (E) ratio of the normalized intensity of 
pMLKL to MLKL, with bacopaside II treatment (n = 1). 
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3.5 Bacopaside II increased PRKCD expression 
Transcriptomic changes in PI3K-Akt-mTOR signalling pathway with 15 µM bacopaside II treatment 
was determined using TaqMan® array human PI3K signalling. Relative to vehicle control, only 
protein kinase C delta transcript (PRKCD) displayed significant change, with a 2.2-fold (p < 0.05) 
increase in transcript expression observed (Figure 7). 
 
Figure 7: Volcano plot of genes in PI3K-Akt-mTOR signalling pathway. Results were 
analysed using multiple t-test with Holm-Sidak correction and FDR adjustment (n = 3). 
3.6 3D-culture promotes stem cell-like phenotype in MDA-MB-231 
To determine if culturing MDA-MB-231 in 3D conditions promoted a stem-cell like phenotype, 
transcript expression of the stem cell markers, OCT4 and NANOG, were measured and compared 
between cells grown as a monolayer (2D) to cells grown as 3D mammospheres for 1-, 3- and 4-week 
(Figure 8). Compared to 2D-cultured cells, OCT4 increased by 2.4-fold (p < 0.0001), 2.6-fold (p < 
0.0001), and 1.8-fold (p < 0.001) after 1-, 3- and 4-week as 3D-cultured cells respectively. Compared 
to 2D-cultured cells, NANOG significantly (p < 0.0001) increased by 28-fold, 48-fold and 34-fold 
after 1-, 3- and 4-weeks as 3D-cultured cells respectively. 


























To determine if 3D-cultured cells maintained this stem cell-like phenotype after subsequent short-
term culture as a monolayer, 4-week 3D-cultured mammospheres were dissociated into single cells 
and cultured as monolayer for 5 days (3D to 2D). Compared to 2D-cultured cells, OCT4 and NANOG 
was 3.9-fold (p < 0.0001) and 34-fold (p < 0.0001) higher respectively, in “3D to 2D” cells. Together, 
these results demonstrated that culturing MDA-MB-231 cells as 3D mammospheres promoted a stem-
cell like phenotype which persisted even after short-term culture as a monolayer. 
  
Figure 8: Stem cell-like phenotype in 3D-cultured and 2D-cultured cells. Transcript 
expression of (A) OCT4 and (B) NANOG of MDA-MB-231 cells in 2D-culture, 3D-
culture and cells that were reseeded (3D to 2D) for drug sensitivity assay. Results were 
analysed using one-way ANOVA test with Dunnett’s multiple comparison and RQ with 






3.7 3D-cultured MDA-MB-231 displayed an increase in resistance to paclitaxel, doxorubicin 
and 5-fluorouracil. 
Since there was an increase in stem-like phenotype in the 3D-cultured MDA-MB-231 cells, these 
cells were further assessed on their response to chemotherapeutics, paclitaxel, doxorubicin and 5-
fluorouracil. IC50 for each drug was measured and resistance was indicated by the increase in IC50 
in 4-week 3D-cultured cells relative to 2D-cultured cells.  
IncucyteS3 confluence data showed an increase in IC50 to paclitaxel (Figure 9A), doxorubicin 
(Figure 9C) and 5-fluorouracil (Figure 9E) by 2.1-fold (p < 0.0001), 2.2-fold (p < 0.0001) and 1.4-
fold (p < 0.0001) respectively, when comparing 3D-cultured cells to 2D-cultured cells.  
Crystal violet assay demonstrated a similar increase in IC50 to paclitaxel (Figure 9B), doxorubicin 
(Figure 9D) and 5-fluorouracil (Figure 9F) of 2.1-fold (p < 0.0001), 3.5-fold (p < 0.0001) and 1.6-









Figure 9: Dose-response curves of chemotherapeutics on 2D-cultured and 3D-
cultured MDA-MB-231. IncucyteS3 and CVA data for (A, B) paclitaxel, (C, D) 
doxorubicin and (E, F) 5-fluorouracil. IC50 with 95% CI were compared between 2D-
cultured and 3D-cultured cells using extra sum-of-squares F-test (n = 6). ****p < 0.0001.  
 
3.8 Efficacy of bacopaside II was not altered in 3D-cultured cells 
The efficacy of bacopaside II was tested on 3D-cultured cell model. No significant difference (p = 
0.71) was observed between the IC50 of bacopaside II in 3D-cultured and 2D-cultured cells, using 
IncucyteS3 (Figure 10A). Similarly, crystal violet assay showed no significant differences (p = 0.45) 
between IC50 of bacopaside II in 3D-cultured and 2D-cultured cells (Figure 10B), confirming 




Figure 10: Dose-response curves of bacopaside II on 2D-cultured and 3D-cultured 
MDA-MB-231. (A) IncucyteS3 and (B) CVA data for bacopaside II dose-response curve. 
IC50 with 95% CI were compared between 2D-cultured and 3D-cultured cells using extra 





Bacopaside II has been reported to have anti-tumour effects such as inhibiting cell growth, migration, 
proliferation and promoting cell death, suggesting its potential as a novel cancer therapeutic20, 21. 
However, the mechanism of cell death of bacopaside II remains unknown. This study is the first to 
investigate the specific mechanism of cell death with bacopaside II treatment, while exploring 
transcriptomic changes in the PI3K-Akt-mTOR signalling pathway (Figure 11). Furthermore, drug 
resistance often develops in TNBC patients7. Hence, a resistant TNBC cell model was established to 
explore the potential of bacopaside II to overcome resistance. 
 
Figure 11: Overview of findings related to methuosis, apoptosis and necroptosis.  
Previously, our group suggested that apoptosis had occurred in MDA-MB-231 cells treated with 
bacopaside II, due to an increase in annexin-V and PI positivity20. This study showed that bacopaside 




Another prominent event that occurred with bacopaside II treatment was the formation of vacuoles, 
similar to methuosis20-22. During methuosis, excessive macropinocytosis will result in colocalization 
of macromolecules, such as TMR-dextran, into vacuoles within the cell24, 25. In this study, 75-kDa 
dextran did not colocalize within the vacuoles, suggesting that macropinocytosis did not occur. 
Methuosis has also been measured using macropinosome markers, in combination with the uptake of 
different sized molecules such as lucifer yellow (457-Da) or TMR-dextran (10- to 75-kDa)23-25, 42. 
Therefore, the occurrence of methuosis with bacopaside II treatment remains inconclusive.  
Subsequently, necroptosis was investigated as a possible mechanism of cell death caused by 
bacopaside II. In this study, higher doses of bacopaside II (≥ 20 µM) caused rapid PI-influx into the 
cell, indicating loss of cell membrane integrity and cell death. Necrostatin-1, an inhibitor of 
necroptosis by upstream inhibition of RIPK1, significantly reduced PI-influx. These findings were 
the first evidence suggesting that bacopaside II may induce necroptosis. However, necrostatin-1 was 
unable to block greater amount of PI-influx, indicating the possibility of other cell death mechanisms 
occurring concurrently such as necrosis.  
To provide further evidence that necroptosis occurred, we measured expression of pMLKL and 
MLKL. We observed basal levels of pMLKL in MDA-MB-231 cells with intact plasma membranes, 
consistent to findings from Liu et al.43. Bacopaside II also increased pMLKL:MLKL in a dose-
dependent manner, corresponding with PI-uptake. These findings suggest that the ratio of pMLKL to 
MLKL may be a critical determinant of necroptotic pore formation. Similarly, others have found 
well-established necroptosis induction method increased pMLKL:MLKL, which coincided with 
increased lactate dehydrogenase release, annexin-V binding and PI-uptake44. Together, this suggests 
that bacopaside II may induce necroptosis. 
To understand the underlying transcriptomic changes with bacopaside II, the PI3K-Akt-mTOR 
signalling pathway was screened. Significant upregulation of PRKCD transcript was observed with 
 
25 
bacopaside II treatment. PRKCD encodes for protein kinase C delta (PKC-δ), which belongs to the 
family of serine and threonine kinase. PKC-δ exhibits both proapoptotic and pro-survival roles in 
breast cancer and its expression is associated with poorer prognosis in breast cancer patients45, 46. 
PKC-δ was found to regulate expression of key necroptosis protein, RIPK3, resulting in increased 
necroptotic cell death in smooth muscle cells47. Similarly, the elevated expression of PRKCD 
coincided with increased cell death and pMLKL:MLKL in this study, suggesting a possible 
relationship between bacopaside II, PKC-δ and necroptosis.  
Lastly, an MDA-MB-231 resistant model associated with increased stem cell-like phenotype was 
established through scaffold-less 3D-culture for four weeks. A previous study by Yousefnia S et al.41 
reported that doxorubicin resistance in scaffold-less 3D-cultured MDA-MB-231 was associated with 
an increase in NANOG and OCT4. Other studies have shown 3D-cultures in hydrogel or matrigel 
scaffolds promotes a stem-cell phenotype and resistance to paclitaxel and doxorubicin in MDA-MB-
23148, 49. In this study, we showed an increase in resistance towards paclitaxel, doxorubicin and 5-
fluorouracil, indicated by increased IC50 in MDA-MB-231 cells grown in scaffold-less 3D-culture, 
as compared to 2D-cultured cells. Resistance in breast CSC can be associated with increased drug 
efflux pumps (ABCG2; breast cancer resistance protein) and overactivation of anti-apoptotic 
signalings (PI3K-Akt-mTOR pathway)50. Unlike other chemotherapeutics in this study, similar IC50 
was found in 2D-cultured and 3D-cultured cells, indicating no increase in resistance towards 
bacopaside II. This shows that this chemotherapy drug resistant model retained sensitivity to 
bacopaside II, suggesting that bacopaside II may have the potential to overcome chemo-resistance in 
cancer patients.  
4.1 Limitations and future directions 
This study focused only on TNBC mesenchymal cell line, MDA-MB-231, and may not be 
representative of other TNBC subtypes. Future studies can include other cell types, including normal 
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cells, to capture a wider perspective of the effects of bacopaside II. This study also lacked positive 
controls such as TSI (TNF, Smac mimetic, IDN-6556) and vacuolin-1 for necroptosis and methuosis 
respectively, which will provide greater certainty to current findings24, 44. Future studies should also 
include key vacuole markers (Rab-7 and LAMP1) and necroptosis proteins (RIPK1, RIPK3) as 
validation for methuosis and necroptosis respectively24, 44. 
Since necroptosis is an immunogenic cell death which releases DAMPs, chemokines, cytokines, and 
recruits cytotoxic T-cells, it has clinical importance as an adjunct to immunotherapy. Patients 
previously unresponsive to immunotherapy may be sensitised following bacopaside II treatment. 
Future in vivo studies will be essential to evaluate the immune response in combination with 
checkpoint inhibition. 
5. Conclusion 
In summary, this study highlights necroptosis as a possible mechanism of cell death of bacopaside II 
in TNBC. Furthermore, efficacy of bacopaside II was not affected in the established resistant model.  
Further studies will be required to validate the mechanism of cell death and determine the potential 
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